Phaseline

Companies › Avidence Therapeutics

Avidence Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AVD275 Intra-articular Injection
Cyclooxygenase (COX) inhibitor
COX1, COX2Phase 1Osteoarthritis of the KneeMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07338266AVD275 Intra-articular InjectionPhase 1Osteoarthritis of the KneeImmunologyMay 2027

Targets

COX1 (1) COX2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.